Skip to main content

Table 6 Health economics questionnaires

From: Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Age

Completed by participant

Completed by parent / guardian (proxy)

 < 1 to < 8 (from 30 days to 7 years inclusive))

None administered

CHU9D (proxy)

8 to < 16 (from age 8 to 15 years inclusive)

CHU9D

EQ-5D-Y (including EQ-VAS -visual analogue scale)a

CHU9D (proxy)

  1. a EQ-5D-Y is recommended for 8–11 as well as 12–16 year olds (p4, https://euroqol.org/docs/EQ-5D-Y-User- Guide.pdf)